Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

Modeling and simulation will be a key component for shift to non-animal methodologies

Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training

From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets

From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets

Publication: Pharmaceuticals
Software: GastroPlus®
Division: PBPK

Candesartan cilexetil, a Biopharmaceutics Classification System (BCS) II prodrug, demonstrates compromised bioavailability attributable to its limited aqueous solubility coupled with P-glycoprotein (P-gp)-mediated efflux and hepatic first-pass metabolism, thereby introducing complexities in generic drug bioequivalence assessments.

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Publication: Crit Rev Toxicol
Software: GastroPlus®
Division: PBPK

Ultraviolet (UV) filters, the active ingredients in sunscreens, have been used for several decades to reduce the risk of acute and chronic damage to the skin from solar UV radiation, which can lead to skin cancer.

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Publication: Crit Rev Toxicol
Software: GastroPlus®
Division: PBPK

Ultraviolet (UV) filters, the active ingredients in sunscreens, have been used for several decades to reduce the risk of acute and chronic damage to the skin from solar UV radiation, which can lead to skin cancer.

Anxiety Disorders, PTSD and OCD: Systematic Review of Approved Psychiatric Medications (2008–2024) and Pipeline Phase III Medications

Anxiety Disorders, PTSD and OCD: Systematic Review of Approved Psychiatric Medications (2008–2024) and Pipeline Phase III Medications

Publication: Drugs Context
Software: GastroPlus®
Division: PBPK

This systematic review examines psychiatric medications approved by the FDA for anxiety disorders, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD) from 2008 to 2024 and describes the mechanism of action, indications for both labelled and off-label uses, evidence for efficacy, dosing and adverse effects for each medication.

Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization

Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization

Publication: Pharmaceutical Research
Software: GastroPlus®
Division: PBPK
Therapeutic Areas: PBPK

This report summarizes the proceedings of Session 1 of the one-day public workshop titled “Advances in PBPK Modeling and its Regulatory Utility for Oral Drug Product Development” hosted by the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) on October 12, 2023.

PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations

PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations

Publication: Pharm Res
Software: GastroPlus®
Division: PBPK

This report summarizes the proceedings for Session 3 of the one-day public workshop entitled “Advances in PBPK Modeling and its Regulatory Utility for Oral Drug Product Development” a jointly sponsored workshop by U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) on October 12, 2023.

Unveiling the Phenolic Profiling of Moroccan Ferula communis L. Fruits: A Combination of In Silico and In Vivo Protective Effect Against Methotrexate-Induced Hepato-Renal Dysfunction

Unveiling the Phenolic Profiling of Moroccan Ferula communis L. Fruits: A Combination of In Silico and In Vivo Protective Effect Against Methotrexate-Induced Hepato-Renal Dysfunction

Publication: Journal of Food Biochemistry
Software: ADMET Predictor®
Division: Cheminformatics

Methotrexate (MTX) is associated with several side effects, including hepatic and renal toxicities, which limit its effectiveness as an anticancer medication.

Longitudinal Model-Based Meta-Analysis (MBMA) Comprehensive MonolixSuite Tutorial with Case Studies

Longitudinal Model-Based Meta-Analysis (MBMA) Comprehensive MonolixSuite Tutorial with Case Studies

Authors: Bracis C
Software: Monolix®

Model-based meta analysis (MBMA) informs key drug development decisions by integrating data, published or unpublished, from multiple studies.